Investment Q&A

Q: Hi 5i Team - Could you provide an update on Intellia, its balance sheet including cash on hand for R&D and day-to-day expenses, as well as insider holdings. Could you also comment on its potential over the next couple of years including info on its third stage trials for new technology which targets mutated genes. It was a top pick on today's (Monday's) Market Call. Thanks.

Q: Hi Team,

Can you please provide your thoughts on NTLA? I've held it for a few years through the ups and downs, and am thinking of now replacing it with something with more potential upside. I was thinking about TOI, but would like to hear if you have any other suggestions as well. My timeframe is 2-3 years.

Thanks

Q: For growth, what do you think about:

NuScale Power Corp
Epsilon Energy
Taylor Devices
Jacobs Engineering
Southwestern Energy
Intellia Therapeutics
Pacific Biosciences of California
Samsung
SK Hynics

Thanks

Q: Hi Peter,

I am not a big fan of ARKK or Cathie Wood. On a year-to-date basis, ARKK has fallen more than 50%. But I am fascinated with Cathie’s all or nothing investment approach. ARKK invests in disruptive technology firms. Her high risk and high reward investment style reminds me of Pete ‘Maverick’ Mitchell in the movies Top Gun and Top Gun Maverick. You either reach Mach 10 or crash and burn!

My question for your team relates to ARKK’s top ten holdings: ZM, TSLA, ROKU, CRSP, EXAS, TDOC, PATH, NTLA, SQ, and BEAM. Which of these stocks have fallen sufficiently so that a high-risk investor can safely purchase them for a five-to-ten-year hold? Also, what is your ranking of these ten high tech disruptive companies? Living life in the “danger zone” has its attractions.

Thanks,

George

Q: Looking at companies in these companies, some have more current business (EXAS) while others are based more on potential. Can you please rank each in order based on these two approaches:

1. Most growth potential
2. Best overall investment

Please comment briefly on why you would place a particular company as "Best in class" for approach 1 and 2.

Q: Hi guys. Would you be able to tell me your ratings on these medical stocks for growth and risk please. It would be a 3 year time frame minimum. Thks again for the great job you do.

Q: Hello,

I took a 1% position, total, in these 3 names about a year ago, as a speculative buy. They have all declined, rather significantly since my initial buy, making all 3 names less than 1% of my total portfolio. I have however noticed some recent relative strength. Would you move on or do you see this area as an interesting speculative buy? To note, I also own a 1.5% position in Illumina. Thanks as always